Darunavir & cobicistat (Rezolsta®)

Assessment Status Rapid review complete
Drug Darunavir & cobicistat
Brand Rezolsta®
Indication Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.
Assessment Process
Rapid review commissioned 02/12/2014
Rapid review completed 08/01/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended